Canseco LM, Liu YW, Lu CC, Lee KC, Chen HH, Hu WH, Tsai KL, Yang YH, Wang CC, Hung CH*. Survival Evidence of Local Control for Colorectal Cancer Liver Metastases by Hepatectomy and/or Radiofrequency Ablation. Cancers (Basel). 2023 Sep 6;15(18):4434. (SCI)
Chang TS, Huang CF, Kuo HT, Lo CC, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Chen CY, Tseng KC, Hung CH*, Yu ML*.
Nguyen-Dinh SH, Li WF, Liu YW, Wang CC, Chen YH, Wang JH, Hung CH*. Comparisons of Viral Etiology and Outcomes of Hepatocellular Carcinoma Undergoing Liver Resection between Taiwan and Vietnam. Viruses. 2022 Nov 20;14(11):2571. (SCI)
Kuo YH, Huang TH, Wang JH, Chen YY, Tsai MC, Chen YH, Lu SN, Hu TH, Chen CH, Hung CH*. Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib. Cancers (Basel). 2022 Aug 17;14(16):3971. (SCI)
Chang TS, Yang YH(co-first), Chen WM, Shen CH, Tung SY, Yen CW, Hsieh YY, Lee CP, Tsai ML, Hung CH*, Lu SN. Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B. Sci Rep. 2021 Jan 14;11(1):1365. (SCI)
Chen WM, Wei KL, Tung SY, Shen CH, Chang TS, Yen CW, Hsieh YY, Chiu WN, Hu JH, Lu SN, Hung CH*. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy. J Formos Med Assoc. 2020 Nov;119(11):1593-1600.(SCI)
Chen WM, Chiang MS, Wang PC, Wei KL, Tung SY, Chang TS, Hung CH*. Esophageal perforation caused by a central venous catheter: A case report and literature review. Adv Dig Med. 2020 June. 7(2): 93-96.
台灣消化醫學雜誌
Liu YW, Lu CC, Chang CD, Lee KC, Chen HH, Yeh WS, Hu WH, Tsai KL, Yeh CH, Wee SY, Yin SM, Wang CC*, Hung CH*. Prognostic value of sarcopenia in patients with colorectal liver metastases undergoing hepatic resection.
Sci Rep. 2020 Apr 15;10(1):6459. (SCI)
Lin SF, Tung SY, Wei KL, Chen CH, Hu TH, Shen CH, Chang TS, Chen WM, Yen CW, Wang JH, Hung CH*, Lu SN.
Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C. PLoS One. 2020 Mar 3;15(3):e0229994. (SCI)
Chen CC, Tung SY, Wei KL, Shen CH, Chang TS, Chen WM, Xu HW, Yen CW, Chen YH, Lu SN, Hung CH*. Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin. J Formos Med Assoc. 2020 Jan;119(1 Pt 3):532-537. (SCI)
Chen CH, Liang CM, Lu CH, Liu YW, Lu SN, Hung CH*. Prognostic factors of radiofrequency ablation therapy for liver metastases from colorectal cancer. Adv Dig Med. 2019 Sep. 6(3): 101-108. 台灣消化醫學雜誌
Chen CH#, Chen CH#, Lin CL, Lin CY, Hu TH, Tung SY, Hsieh SY, Lu SN, Chien RN, Hung CH*, Sheen IS. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir?±?ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. Sci Rep. 2019 May 8;9(1):7086. (SCI)�
Chu MO, Shen CH, Chang TS, Xu HW, Yen CW, Lu SN, Hung CH*. Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation. Sci Rep. 2018 Nov 9;8(1):16611. (SCI)
Espinosa W, Liu YW, Wang CC, Lin CC, Wang JH, Lu SN, Hung CH*. Combined resection and radiofrequency ablation versus transarterial embolization for intermediate-stage hepatocellular carcinoma: A propensity score matching study. J Formos Med Assoc. 2018 Mar;117(3):197-203. (SCI)
Hung CH*, Kee KM, Chen CH, Tseng PL, Tsai MC, Chen CH, Wang JH, Chang KC, Kuo YH, Yen YH, Hu TH, Lu SN. A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation. Clin Transl Gastroenterol. 2017 Jun 29;8(6):e104. (SCI)
Hung CH*, Wang JH, Lu SN, Hu TH, Lee CM, Chen CH*. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy. J Viral Hepat. 2017 Jul;24(7):599-607. (SCI)
Tsai MC, Chen CH, Hu TH, Lu SN, Lee CM, Wang JH, Hung CH*.Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. J Formos Med Assoc. J Formos Med Assoc. 2017 Jul;116(7):512-521. (SCI)
Tsai MC, Chen CH, Hu TH, Lu SN, Lee CM, Wang JH, Hung CH*.Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. J Formos Med Assoc.
Hung CH*, Kee KM, Chen CH, Tseng PL, Tsai MC, Chen CH, Wang JH, Chang KC, Kuo YH, Yen YH, Hu TH, Lu SN. A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation.
Hung CH*, Hu TH, Lu SN, Chen CH, Wang JH, Lee CM. Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C. J Formos Med Assoc. 2016 Apr;115(4):278-83. (SCI)
Hung CH*, Hu TH, Lu SN, Kuo FY, Chen CH, Wang JH, Huang CM, Lee CM, Lin CY, Yen YH, Chiu YC. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus. Int J Cancer. 2016 Feb 1;138(3):714-20. (SCI)
Hung CH, Hu TH, Lu SN, Lee CM, Chen CH, Kee KM, Wang JH, Tsai MC, Kuo YH, Chang KC, Chiu YC, Chen CH*. Tenofovir versus Entecavir in Treatment of Chronic Hepatitis B Virus with Severe Acute Exacerbation. Antimicrob Agents Chemother. 2015 Jun;59(6):3168-73. (SCI)
Kuo MT, Hu TH, Lu SN, Hung CH*, Wang JH, Chen CH, Chiu YC, Lee CM. Neutrophil-to-Lymphocyte Ratio as a Predictor of Response to Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C. Dis Markers. 2014;2014:462958. (SCI)
Yang CH, Chiu YC, Chen CH, Chen CH, Tsai MC, Chuah SK, Lee CH, Hu TH, Hung CH*. Diabetes mellitus is associated with gastroesophageal variceal bleeding in cirrhotic patients. Kaohsiung J Med Sci. 2014 Oct;30(10):515-20. (SCI)
Hung CH*, Chiu YC, Hu TH, Chen CH, Lu SN, Huang CM, Wang JH, Lee CM. Significance of Vitamin D Receptor Gene Polymorphisms for Risk of Hepatocellular Carcinoma in Chronic Hepatitis C. Transl Oncol. 2014 Aug;7(4):503-7.(SCI)
Chen CH, Chiu YC, Lu SN, Lee CM, Wang JH, Hu TH, Hung CH*. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. World J Gastroenterol. 2014 Jun 28;20(24):7686-7695. (SCI)
Hung CH*, Chiu YC, Chen CH, Hu TH. MicroRNAs in Hepatocellular Carcinoma: Carcinogenesis, Progression, and Therapeutic Target. Biomed Res Int. 2014;2014:486407. Review. (SCI)
Liang CM, HU TH, Lu SN, Hung CH*, Huang CM, Wang JH, Yen YH, Chen CH, Chang KC, Tsai MC, Kuo YH, Lee CM. Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy. J Viral Hepat. 2013 Nov.; 20(11)761-769. (SCI)
Hung CH*, Chen CH, Lee CM, Hu TH, Lu SN, Wang JH, Huang CM. Role of viral genotypes and hepatitis B viral mutants in the risk of hepatocellular carcinoma associated with hepatitis B and C dual infection. Intervirology. 2013 Sep;56(5):316-24. (SCI)
Hung CH, Chang KC, Lu SN, Wang JH, Chen CH, Lee CM, Hu TH*. Spontaneous clearance of hepatitis C virus in an interleukin 28B favorable genotype highly prevalent area. Hepatology. 2013 May;57(5):2089-90. (SCI)
Hung CH*, Hu TH, Lee CM, Huang CM, Chen CH, Wang JH, Lu SN. Amino acid substitutions in the core region associate with insulin resistance in chronic hepatitis C. Intervirology. 2013 May;56(3):166-71. (SCI)
Hung CH, Chen CH, Lu SN, Wang JH, Hu TH, Huang CM, Tsai MC, Lee CM*. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy. Antiviral Res. 2012;93:55-63. (SCI)
Liang CM, Wang MC, Chen YJ, Hung CH*, Hu TH. Primary Duodenal Mucosa-Associated Lymphoid Tissue Lymphoma: Report of a Case. Gastroenterol J Taiwan 2011 Sep; 28(3):310-316.
Xu HW, Wu KL, Wang JH, Tsai MS, Hung CH*, Chiou SS, Changchien CS, Hu TH, Lu SN, Chuah SK. Comparison of cefazolin and ceftriaxone as prophylactic antibiotic in cirrhotic patients with acute variceal hemorrhage after endoscopic interventions. Gastroenterol J Taiwan 2011 Sept.; 28(3): 289-298.
Hung CH, Lee CM, Lu SN*. Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. Expert Rev Anti Infect Ther.2011;9:525-33. (SCI)
Hung CH, Lu SN, Wang JH, Hu TH, Chen CH, Huang CM, Lee CM*. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. Antivir Ther. 2011;16:959-968. (SCI)
Hung CH, Lee CM, Wang JH, Hu TH, Chen CH, Lin CY, Lu SN*. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer. 2011;128:2344-2352. (SCI)
Kuo YH, Chuang TW, Hung CH*, Chen CH, Wang JH, Hu TH, Lu SN, Lee CM. Reversal of hypolipidemia in chronic hepatitis C patients after successful antiviral therapy. J Formos Med Assoc. 2011;110:363-71. (SCI)
Hung CH*, Lee CM, Lu SN, Wang JH, Chen CH, Hu TH. Hepatic steatosis with hepatitis B virus/hepatitis C virus dual infection. Hepatology. 2010;52:1521-1522. (SCI)
Chen CH, Lee CM, Chen CH, Hu TH, Wang JH, Hung CH*, Chung CH, Lu SN. Prevalence and clinical relevance of serum autoantibodies in patients with chronic hepatitis C. Chang Gung Med J. 2010 May-Jun;33(3):258-65.
Hung CH*, Wang JH, Hu TH, Chen CH, Chang KC, Yen YH, Kuo YH, Tsai MC, Lu SN, Lee CM. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol. 2010;16:2265-2271. (SCI)
Hung CH*, Lee CM, Chen CH, Hu TH, Jiang SR, Wang JH, Lu SN, Wang PW. Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C. Liver Int. 2009;29:1086-1093. (SCI)
Tsai MC, Lin MC, Hung CH*. Successful antiviral and antitubercular treatment in a chronic hepatitis C patient with reactivation of pulmonary tuberculosis during pegylated interferon-alfa plus ribavirin therapy. J Formos Med Assoc. 2009;108:746-750. (SCI)
Kuo YH, Wang JH, Lu SN, Hung CH*, Wei YC, Hu TH, Chen CH, Yen YH, Lee CM, Eng HL. Natural course of hepatic focal nodular hyperplasia: a long-term follow-up study with sonography. J Clin Ultrasound. 2009;37:132-137.
Hung CH, Lee CM*. Treatment guideline for chronic hepatitis C genotype 1 and genotype 4. 病毒基因型第一型與第四型慢性C型肝炎之治療指引. Gastroenterol J Taiwan 2008; 25:34-39.
Hung CH, Lu SN, Wang JH, Hung SF, Chen CH, Hu TH, Lee CM, Changchien CS*. Identified cases of acute hepatitis C from computerized laboratory database: a hospital based epidemiological and clinical study. J Infect. 2008;56:274-280. (SCI)
Hung CH*, Lee CM, Kuo FY, Jiang SR, Hu TH, Chen CH, Wang JH, Lu SN, Eng HL, Changchien CS. Steatosis correlates with hepatic expression of death receptors and activation of nuclear factor-kappa B in chronic hepatitis C. Liver Int. 2008;28:339-346. (SCI)
Hung CH, Chen CH, Lee CM*, Wu CM, Hu TH, Wang JH, Yen YH, Lu SN. Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma. J Viral Hepat. 2008;15:58-65. (SCI)
Chuang TW, Hung CH*, Huang SC, Lee CM. Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glomerulopathy after lamivudine monotherapy. J Formos Med Assoc. 2007;106:869-873. (SCI)
Hung CH, Lee CM*, Lu SN, Wang JH, Chen CH, Hu TH, Kee KM, Chang KC, Tseng PL, Yen YH, Changchien CS. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver Int. 2006;26:1079-1086. (SCI)
Hung CH, Kuo FY, Wang JH, Lu SN, Hu TH, Chen CH, Lee CM*, Eng HL. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy. Antivir Ther. 2006;11:483-9. (SCI)
Hung CH, Lee CM*, Lu SN, Wang JH, Hu TH, Tung HD, Chen CH, Chen WJ, Changchien CS. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2006;13:409-414. (SCI)
Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN*. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol. 2005;20:1553-1559. (SCI)
Hung CH, Lee CM*, Lu SN, Wang JH, Tung HD, Chen CH, Changchien CS. Combination Therapy with Interferon-alpha and Ribavirin in Patients with Dual Hepatitis B and Hepatitis C Virus Infection. J Gastroenterol Hepatol. 2005;20:727-732. (SCI)
Hung CH, Lee CM*, Wang JH, Chen CH, Lu SN. Acute hepatitis B virus superinfection in a Taiwanese patient with chronic hepatitis C. J Formos Med Assoc. 2004;1034:302-5. (SCI)
Hung CH, Lu SN*, Wang JH, Lee CM, Chen TM, Tung HD, Chen CH, Huang WS, Changchien CS. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol. 2003;38:153-7. (SCI)
Hung CH, Lee CM*, Lu SN, Lee JF, Wang JH, Tung HD, Chen TM, Hu TH, Chen WJ, Changchien CS. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. J Viral Hepat. 2003;10:87-94. (SCI)
Hung CH, Lee CM, Lu SN, Wang JH, Tung HD, Chen TM, Chen CH, Changchien CS. Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy? J Gastroenterol Hepatol. 2002;17: 1307-1311. (SCI)
Hung CH, Changchien CS*, Lu SN, Eng HL, Wang JH, Lee CM, Hsu CC, Tung HD. Sonographic features of hepatic adenomas with pathologic correlation. Abdom Imaging 2001;26:500-6. (SCI)
